Ganga Pharmaceuticals Ltd
Incorporated in 1989, Ganga Pharmaceuticals Ltd is in the business of manufacturing & trading in Ayurvedic pharmaceuticals & allied products[1]
- Market Cap ₹ 6.44 Cr.
- Current Price ₹ 13.3
- High / Low ₹ 27.1 / 9.25
- Stock P/E 322
- Book Value ₹ 13.2
- Dividend Yield 0.00 %
- ROCE 3.35 %
- ROE 0.37 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.01 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last 3 years: -10.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| 3.08 | 2.37 | |
| 2.70 | 2.34 | |
| Operating Profit | 0.38 | 0.03 |
| OPM % | 12.34% | 1.27% |
| 0.17 | 0.25 | |
| Interest | 0.24 | 0.19 |
| Depreciation | 0.05 | 0.05 |
| Profit before tax | 0.26 | 0.04 |
| Tax % | 23.08% | 50.00% |
| 0.19 | 0.02 | |
| EPS in Rs | 0.47 | 0.05 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -89% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| 1 Year: | -46% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Equity Capital | 4.06 | 4.06 |
| Reserves | 1.29 | 1.31 |
| 1.45 | 1.55 | |
| 0.77 | 0.74 | |
| Total Liabilities | 7.57 | 7.66 |
| 0.76 | 0.72 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.09 | 0.09 |
| 6.72 | 6.85 | |
| Total Assets | 7.57 | 7.66 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| -0.31 | -0.18 | |
| 0.37 | 0.28 | |
| -0.29 | -0.10 | |
| Net Cash Flow | -0.22 | 0.00 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Debtor Days | 126.80 | 126.29 |
| Inventory Days | 296.56 | 332.62 |
| Days Payable | 159.69 | 129.52 |
| Cash Conversion Cycle | 263.68 | 329.39 |
| Working Capital Days | 432.55 | 592.93 |
| ROCE % | 3.35% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Ganga Pharma exempt from Annual Secretarial Compliance Report for FY 2025 due to SME listing and capital criteria.
-
Statement Of Deviation And Variation
20 May - No deviation in utilization of Rs.1.70 Cr raised via preferential issue as of Mar 31, 2025.
-
Results
20 May - Audited financial results for FY ended March 31, 2025, with net profit of Rs.7.90 lakhs and unmodified auditor opinion.
-
Board Meeting Outcome for Held On May 20, 2025
20 May - Audited financial results for FY ended March 31, 2025 with unmodified audit opinion disclosed.
-
Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results For The Half And Financial Year Ended On March 31 2025.
6 May - Board meeting on May 20 to approve audited financial results for FY ending March 31, 2025.
Annual reports
Concalls
-
May 2024TranscriptNotesPPT
Business Overview:[1][2]
Company does production of Ayurvedic Medicines by using techniques strictly as per Ancient text and Ayurved pharma companies. Apart from manufacturing, it is also into marketing and distribution of Bulk Ayurvedic Medicines in Mumbai